ArticleObesity science & practice2019
ANGPTL4 gene E40K variation protects against obesity-associated dyslipidemia in participants with obesity.
Article in Obesity science & practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Obesity genetic association prospective cohort utilizing single center real-world evidence data.Medicine · 2025Article
- Adipose Factor ANGPTL4: Its Role in Aging Mechanisms and Associated Diseases.Clinical interventions in aging · 2025Review
- ANGPTL4-the Link Binding Lipid Metabolism and Inflammation.Current medicinal chemistry · 2025Review
- Assessment of Two Potential Probiotic Strains As Anti-Obesity Supplements Under High-Fat Feeding Conditions.Probiotics and antimicrobial proteins · 2023Article
- ANGPTL4 is a potential driver of HCV-induced peripheral insulin resistance.Scientific reports · 2023Article
- Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis.Handbook of experimental pharmacology · 2022Article
- Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice.The Journal of clinical investigation · 2021Article
- Regulation of plasma triglyceride partitioning by adipose-derived ANGPTL4 in mice.Scientific reports · 2021Article
- Cross-talk between ANGPTL4 gene SNP Rs1044250 and weight management is a risk factor of metabolic syndrome.Journal of translational medicine · 2021Article
- Angiopoietin-Like Protein 4 Overexpression in Visceral Adipose Tissue from Obese Subjects with Impaired Glucose Metabolism and Relationship with Lipoprotein Lipase.International journal of molecular sciences · 2020Article
- Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids.Journal of lipid research · 2020Article
- Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake.Comprehensive Physiology · 2020Review
- ANGPTL4 in Metabolic and Cardiovascular Disease.Trends in molecular medicine · 2019Review
- ANGPTL4 gene E40K variation protects against obesity-associated dyslipidemia in participants with obesity.Obesity science & practice · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveANGPTL4 inhibits lipoprotein lipase in adipose tissue, regulating plasma triglycerides levels. In persons with obesity plasma ANGPTL4 levels have been positively correlated with body fat mass, TG levels and low HDL. A loss-of-function E40K mutation in
methods
resultsParticipants with obesity carrying the E40K variant had significantly lower TG (
conclusionsIn participants with obesity the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.